Breast Cancer Surge in India: 477% Rise in Cases Since 1990 – IHME Study Highlights Global Health Gap — UPSC Current Affairs | March 4, 2026
Breast Cancer Surge in India: 477% Rise in Cases Since 1990 – IHME Study Highlights Global Health Gap
A Lancet Oncology study led by IHME shows India's breast cancer cases surged 477% and deaths 352% from 1990 to 2023, highlighting stark contrasts with high‑income nations where mortality is falling. The findings underscore urgent UPSC‑relevant policy needs for improved screening, early diagnosis, and lifestyle interventions in low‑ and middle‑income settings.
Overview The recent Lancet Oncology study led by Kayleigh Bhangdia of the Institute for Health Metrics and Evaluation (IHME) projects a sharp rise in breast cancer burden worldwide, with India witnessing a **477% increase in cases** and **352% rise in deaths** from 1990 to 2023. Key Developments Global cases expected to reach **3.5 million by 2050**, a one‑third rise from 2023. Annual deaths could climb to **1.37 million**, a **44% increase**. India recorded **2.03 lakh cases** in 2023, up **477%** since 1990, with **over 1 lakh deaths** (352% rise). Low‑ and middle‑income countries (LMICs) show a **147.2% surge** in age‑standardised incidence rate (ASIR) , while high‑income nations see only **1.2%** growth. High‑income nations experienced a **‑29.9% decline** in age‑standardised mortality rate (ASMR) , contrasted with a **99.3% rise** in LMICs. Important Facts The disparity stems from differences in screening programmes, early diagnosis, and treatment infrastructure . High‑income countries benefit from organized mammography, advanced therapeutics, and robust health financing, leading to stable incidence and falling mortality. In contrast, LMICs face delayed diagnosis, limited access to quality care, and higher fatality rates, threatening gains in women’s health. Preventive measures—**non‑smoking, regular physical activity, reduced red‑meat intake, and maintaining healthy weight**—could avert over **25% of healthy years lost** to breast cancer, underscoring the role of lifestyle in disease control. UPSC Relevance Understanding this health trend is vital for multiple GS papers: GS4 (Health & Family Welfare) : Analyses of disease burden, health‑system gaps, and preventive strategies. GS3 (Economy) : Impact of cancer on productivity, health‑care expenditure, and insurance frameworks. GS2 (Polity) : Role of government schemes (e.g., National Cancer Control Programme) and regulatory bodies in scaling screening. Way Forward Policy recommendations for India and similar LMICs include: Establish **nationwide, affordable screening** (clinical breast examination, low‑cost imaging) targeting women aged 30‑49. Strengthen **primary health‑care linkages** for timely referral and treatment. Increase **public‑private partnerships** to expand oncology infrastructure and subsidise chemotherapy/radiotherapy. Integrate **health‑promotion campaigns** on lifestyle risk factors within existing Swasthya Sankalp initiatives. Utilise **IHME data** for evidence‑based resource allocation and monitoring of progress toward Sustainable Development Goal 3.4 (reduce premature mortality from non‑communicable diseases). Addressing the rising breast cancer burden will require coordinated action across health, finance, and social sectors, aligning with India’s broader agenda of universal health coverage and gender equity.
Login to bookmark articles
Login to mark articles as complete
Overview
Breast cancer cases in India surged 477% since 1990, exposing health‑system gaps
Key Facts
India recorded 2.03 lakh breast cancer cases in 2023 – a 477% rise from 1990.
Breast‑cancer deaths in India rose 352% over the same period, exceeding 1 lakh in 2023.
Global breast‑cancer incidence is projected to reach 3.5 million by 2050 (≈33% increase from 2023).
Low‑ and middle‑income countries (LMICs) saw a 147.2% rise in age‑standardised incidence rate (ASIR); high‑income nations rose only 1.2%.
ASMR declined by 29.9% in high‑income nations but surged 99.3% in LMICs.
Preventable lifestyle factors could avert >25% of healthy‑years lost to breast cancer.
Background & Context
The sharp rise in breast‑cancer burden underscores gaps in screening, early diagnosis and treatment infrastructure, linking directly to the UPSC syllabus on health‑system financing, NCD control (GS4) and the economic impact of disease on productivity and health‑care expenditure (GS3). It also ties to SDG‑3.4 and gender‑equity objectives.
Mains Answer Angle
GS3 – Analyse the economic implications of the escalating breast‑cancer burden in India and evaluate policy measures needed to mitigate productivity loss and health‑care costs.